Rep. Jess Edwards
Sponsored bills
Maddy summaryHB 455 requires the New Hampshire Department of Health and Human Services to submit annual reports to the legislature on Medicaid enhancements for children and pregnant women. The bill mandates specific data on enrollment, eligibility, and program effectiveness, directly affecting the state agency responsible for administering Medicaid. Key provisions include standardized reporting templates and deadlines to ensure transparency about how these enhancements operate. The bill was signed into law by Governor Ayotte on May 29, 2025, and takes effect July 1, 2025.
Maddy summaryHB 99 amends the law concerning property tax credits for disabled veterans. The bill increases the maximum optional tax credit for veterans with a service-connected permanent and total disability from $4,000 to $5,000. It clarifies that this optional credit, which cities and towns can choose to adopt, replaces other specific tax credits for veterans and is not an additional benefit. This change directly affects qualifying disabled veterans and the municipalities that offer this property tax credit.
Maddy summaryHB 66 amends the state's Right to Know law, specifically addressing appeals of ombudsman rulings related to public record disclosures. The bill removes the provision that exempted citizen-initiated appeals to the superior court from filing fees or surcharges, meaning these appeals would now incur such costs. It also outlines procedures for these appeals, including a 30-day filing window and the requirement for the superior court to consider the ombudsman's ruling. Public bodies or agencies would be responsible for sheriff's service costs if they decline service.
Maddy summaryHB 645 requires the Prescription Drug Affordability Board to establish a formal agreement (MOU) with the Department of Health and Human Services and other state agencies for sharing data. This bill directly affects the Board and state agencies by mandating that agencies share requested data to help the Board fulfill its duties, while minimizing duplicate data collection. Key provisions include modifying existing MOUs where possible, requiring agencies to release data upon request, and including cost-sharing terms in the agreement. The bill streamlines data access without creating new drug pricing policies or altering the Board’s core responsibilities.